Emyria Ltd AI Stock Analysis
Want to see AU:EMD full AI Analyst Report?
Emyria Ltd (EMD) AI Stock Analysis
Emyria Ltd
(ASX:EMD)
The overall score is very low, driven primarily by severe financial distress. The company's core operations are deeply unprofitable with negative gross margins and significant cash burn, which is the most critical risk. This is compounded by a bearish technical trend with the stock in a sustained downtrend across all major moving averages. The only mitigating factor is a conservative balance sheet with low debt, which provides a temporary financial cushion but does not resolve the fundamental business model challenges.
Emyria Ltd (EMD) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 29.85M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.48M
- Price to Earnings (P/E)
- -4.6
- Beta (1Y)
- 1.25
- Revenue Growth
- 178.16%
- EPS Growth
- -15.71%
- Country
- Australia
- Employees
- 6
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Emyria Ltd Business Overview & Revenue Model
Company Description
Emyria Limited is a biotechnology firm currently in the clinical stage, dedicated to creating therapies for medical conditions that lack effective treatments. The company's work primarily involves the development of cannabinoid-derived pharmaceutical...
Emyria Ltd Financial Statement Overview
Summary
Financial performance is weak. The income statement shows deeply negative gross margins (-94.3%) and substantial net losses (-A$6.1M) despite 178% revenue growth. Cash flow is a major concern with -A$4.9M free cash outflow. The balance sheet is the only bright spot, with low debt (D/E 0.09) and growing equity, providing a runway but not offsetting the severe unprofitability.
Income Statement
18Very NegativeBalance Sheet
55NeutralCash Flow
25Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.88M | 3.88M | 1.39M | 2.20M | 1.59M | 1.82M |
| Gross Profit | -3.66M | -3.66M | 24.48K | -167.55K | -3.32M | -4.41M |
| EBITDA | -5.81M | -5.81M | -2.03M | -13.03M | -6.69M | -8.03M |
| Net Income | -6.11M | -6.11M | -3.14M | -11.46M | -5.13M | -7.33M |
Balance Sheet | ||||||
| Total Assets | 11.49M | 11.49M | 6.62M | 5.43M | 10.16M | 8.25M |
| Cash, Cash Equivalents and Short-Term Investments | 7.29M | 7.29M | 3.57M | 1.57M | 2.73M | 3.88M |
| Total Debt | 787.38K | 787.38K | 613.50K | 1.72M | 1.27M | 632.70K |
| Total Liabilities | 2.65M | 2.65M | 1.31M | 3.00M | 3.37M | 1.93M |
| Stockholders Equity | 8.85M | 8.85M | 5.31M | 2.43M | 6.79M | 6.32M |
Cash Flow | ||||||
| Free Cash Flow | -4.92M | -4.92M | -2.72M | -4.44M | -7.01M | -7.46M |
| Operating Cash Flow | -4.56M | -4.56M | -2.70M | -4.28M | -3.77M | -5.43M |
| Investing Cash Flow | -546.59K | -546.59K | 81.07K | -1.38M | -3.23M | -2.03M |
| Financing Cash Flow | 8.82M | 8.82M | 4.63M | 4.50M | 5.86M | 4.81M |
Emyria Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMD, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.04, and below the 200-day MA of 0.05, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 32.64 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EMD.
Emyria Ltd Peers Comparison
Overall Rating
AU:CGS77Outperform
AU:ALC63Neutral
AU:DOC60Neutral
AU:ONE51Neutral- AU:EMD40Underperform
AU:BMT40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:CGS | 77Outperform | AUD 649.08M | 35.48 | 21.61% | 1.10% | 6.95% | 10.77% |
| AU:ALC | 63Neutral | AUD 141.73M | 67.65 | 2.53% | ― | 26.61% | 41.67% |
| AU:DOC | 60Neutral | AUD 42.17M | 16.36 | 90.90% | ― | 5.35% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:ONE | 51Neutral | AUD 117.49M | -6.72 | -203.69% | ― | -1.53% | 28.29% |
| AU:EMD | 40Underperform | AUD 30.65M | -4.57 | -58.38% | ― | 178.16% | -15.71% |
| AU:BMT | 40Underperform | AUD 21.26M | -1.08 | -58.13% | ― | 2.08% | -195.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:EMD | Emyria Ltd | 0.04 | -0.03 | -43.94% | |
| AU:CGS | Cogstate Ltd | 3.64 | 0.98 | 36.64% | |
| AU:ONE | Oneview Healthcare PLC Chess Depository Interests repr 1 | 0.14 | -0.13 | -48.15% | |
| AU:BMT | Beamtree Holdings Ltd | 0.07 | -0.13 | -66.00% | |
| AU:ALC | Alcidion Group Limited | 0.12 | 0.01 | 4.55% | |
| AU:DOC | Doctor Care Anywhere Group PLC Shs Chess Depository Interests Repr 1 sh | 0.12 | -0.01 | -11.54% |
Emyria Ltd Corporate Events
Emyria signals ambition in global psychedelic treatment push
Emyria Ltd is positioning itself within the emerging psychedelic healthcare sector, concentrating on the development of regulated, science-based treatment programs. The company’s strategy targets patients who have limited options under current mental...
Emyria lodges updated ASX corporate governance disclosures
Emyria Limited has confirmed that its corporate governance framework complies with the ASX Corporate Governance Council Principles and Recommendations for the year ended 30 June 2026. The company has implemented a board charter, formal appointment ag...
Emyria sets November date for electronically managed AGM
Emyria Ltd has called its Annual General Meeting of shareholders for 2:00 p.m. AWST on 12 November 2026 at Stantons International’s offices in West Perth, Western Australia. The company is shifting to electronic distribution of meeting materials, mak...
Emyria Director Professor Sir John Tooke to Retire as Board Succession Review Begins
Emyria Limited has announced that Non-Executive Director Professor Sir John Tooke will retire from its board following the annual general meeting on 12 November 2026, stepping down to focus on personal endeavours after more than six years of service....
Emyria Taps Former U.S. VA Secretary Shulkin to Bolster U.S. Psychedelic Strategy
Emyria has released a pre-recorded investor webinar featuring Executive Chairman Greg Hutchinson and newly appointed Strategic Advisor Dr David Shulkin, a former U.S. Secretary of Veterans Affairs with deep experience in leading large-scale healthcar...
Emyria options lapse as 7.85 million EMDAW securities expire unexercised
Emyria Ltd has reported the expiry of a tranche of options listed under the code EMDAW, which were due to expire on 5 October 2026 at an exercise price of $0.12. A total of 7,854,778 options lapsed without being exercised, reducing the volume of pote...
Emyria Ltd Seeks ASX Quotation for Additional Ordinary Shares
Emyria Ltd has applied for the quotation of 125,000 new ordinary fully paid shares on the ASX, expanding its listed securities under the code EMD. The issuance, dated 24 September 2026, reflects the company’s ongoing use of equity markets to support...
Emyria taps former U.S. VA Secretary Shulkin to drive U.S. psychedelic strategy
Emyria has appointed former U.S. Secretary of Veterans Affairs Dr David Shulkin as a Strategic Advisor, bolstering its U.S. strategy with senior federal healthcare and veterans’ health expertise. Shulkin, who previously led one of the world’s largest...
Emyria takes Australian psychedelic treatment model to U.S. FDA
Emyria Limited, an Australian leader in innovative mental health treatments, specialises in psychedelic-assisted therapy delivered through regulated clinical settings. The company has built comprehensive capabilities across governance, training, infr...
Emyria flags safety risks and regulatory hurdles for experimental psychedelic therapies
Emyria’s latest investor update reiterates that its pipeline of MDMA, psilocybin and MDMA-inspired therapies remains at an experimental stage, with no products yet approved by Australia’s Therapeutic Goods Administration. The company stresses that sa...
Emyria Doubles Revenue but Posts Wider Annual Loss
Emyria Limited reported a sharp increase in revenue for the year ended 30 June 2026, with income from customer sales and clinical services rising 191% to $4.05 million and total revenue reaching $4.34 million. Despite this growth, the group’s net los...
Emyria Sets 2026 AGM Date and Highlights Psychedelic Therapy Risks
Emyria Limited has scheduled its 2026 annual general meeting for 2.00pm WST on 12 November 2026 at Stantons International in West Perth, with director re-elections on the agenda. The company has set 24 September 2026 as the deadline for director nomi...
Emyria Moves to Expand Psychedelic Treatment Capacity Ahead of Q4
Emyria has resolved authorised prescriber capacity constraints across its Perth and Queensland mental health clinics, removing a key bottleneck to expanding psychedelic-assisted treatment services. With prescribing approvals in place, the limiting fa...
Emyria Options Lapse, Trimming Potential Share Dilution
Emyria Ltd, listed on the ASX under ticker EMD, lodged an Appendix 3H notice detailing changes to its issued capital. The company advised that a class of options tied to its securities has reached expiry and no longer forms part of its outstanding ca...
Emyria relocates head office as it advances psychedelic-assisted therapy programs
Emyria Limited, an Australian mental health and neurological treatment developer, combines evidence-based clinical services, real-world data gathering, and a pipeline of psychedelic-assisted therapies and drug candidates. Its Emyria Healthcare divisi...
Emyria accelerates national Empax rollout as revenues surge and clinical data impress
Emyria reported quarterly revenue of about $1.53 million and FY26 revenue of approximately $4.3 million, more than double the prior year, driven by clinic growth and insurer-funded patient demand. The company’s Victorian Empax clinic on the Morningto...
Emyria invites investors to quarterly update amid progress in experimental mental health therapies
Emyria Limited has invited investors to a quarterly webinar on 30 July 2026, where Executive Chairman Greg Hutchinson and Chief Operating Officer Mary-Ann Rennie will discuss the company’s June 2026 activities and outline expectations for the coming...
Emyria underscores risks and regulatory hurdles in psychedelic mental health therapies
Emyria has outlined its role in developing and delivering advanced mental health therapies, emphasising psychedelic-assisted psychotherapy using MDMA, psilocybin and MDMA-inspired compounds in tightly controlled clinical settings. The company stresse...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026